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Selenium and methionine sulfoxide reduction
Hwa-Young Kim & Vadim N. Gladyshev
Department of Biochemistry, University of Nebraska–Lincoln
Summary: Methionine residues in proteins can be readily oxidized to a diastereomeric
mixture of methionine sulfoxides by reactive oxygen species. In most organisms,
methionine sulfoxides are reversibly and stereospecifically reduced back to methionine by two distinct classes of repair enzymes, methionine-S-sulfoxide reductase
(MsrA) and methionine-R-sulfoxide reductase (MsrB). Methionine sulfoxide reduction is thought to be an essential pathway that protects cells from oxidative stress and
regulates protein function. This pathway is also implicated in delaying the aging process in organisms from yeast to mammals. The first selenoprotein identified using bioinformatics methods, SelR (also known as SelX or MsrB1), was recently found to be a
selenocysteine-containing MsrB. In mammals, selenoprotein MsrB1 is a major MsrB,
while MsrB2 and MsrB3 contain cysteine in place of selenocysteine. It has been found
that selenocysteine- and cysteine-containing MsrBs employ different catalytic mechanisms. Interestingly, a selenocysteine-containing form of MsrA was also described, but
so far was only detected in green algae.

Introduction
Selenium is an essential trace element in humans and other mammals. It is cotranslationally incorporated into proteins in the form of the 21st amino acid,
selenocysteine (Sec) [1–3]. The Sec-containing proteins, selenoproteins, are
found in all three kingdoms of life. Twenty five selenoprotein genes have been
identified in human and 24 in rodent genomes [4]. A limited number of selenoproteins have been characterized while functions and physiological roles of
many other selenoproteins have yet to be determined. Among selenoproteins
with known functions the majority are oxidoreductases, for example, glutathione peroxidase [5], thioredoxin reductase [6] and formate dehydrogenase [7].
Selenoproteins typically exhibit 100-1,000 fold higher enzyme activities than
their cysteine (Cys) mutants or natural Cys-containing forms. A key reason
for the use of Sec in biological systems is explained by this high catalytic activity of Sec-containing enzymes. For incorporation of Sec at in-frame UGA
codons, cis- and trans-acting factors are required, including Sec insertion se123
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quence (SECIS) element, SECIS-binding proteins, tRNA[Ser]Sec, and Sec-specific elongation factor [3,8].
In 1999, initial bioinformatics methods were developed for identification
of selenoprotein genes by searching for SECIS elements (see Chapter 9). The
first selenoprotein identified using this approach was designated as selenoprotein R (SelR) [9]. Independently, it was described as selenoprotein X (SelX)
[10]. Comparative genomic analyses were then used to link the function of
SelR to the pathway of methionine sulfoxide reduction, and this prediction
was verified experimentally [11].
Proteins can be oxidized by reactive oxygen species (ROS) generated in
cells during stress and physiological processes. Methionine residues in proteins are among the most susceptible to oxidation by ROS and are converted
by these species to methionine sulfoxide. A diastereomeric mixture of methionine-S-sulfoxide and methionine-R-sulfoxide is generated by ROS because of
the presence of chiral sulfur in methionine sulfoxides [12]. Generation of methionine sulfoxides may manifest significant structural and functional changes
in proteins. However, methionine sulfoxide can be reduced back to methionine by repair enzymes, methionine sulfoxide reductases. Therefore, methionine sulfoxide reduction is thought to be an important pathway that protects
cells against oxidative stress, regulates protein function, and delays the aging
process [13-17].
This chapter will focus on methionine sulfoxide reduction in mammals and
the role of selenium in this pathway.
Methionine sulfoxide reductases
Methionine sulfoxide reductases reduce free and protein-bound methionine
sulfoxides back to methionine in the presence of thioredoxin (Trx) or dithiothreitol (DTT) [18,19]. To catalyze the repair process, two distinct stereospecific
enzymes are evolved. MsrA can only reduce the S epimer of methionine sulfoxide, whereas MsrB is specific for the R form of this amino acid (Figure 1).
Most organisms from bacteria to humans contain MsrA and MsrB genes
in their genomes. However, some hyperthermophiles and intracellular parasites do not have MsrA, MsrB, or both proteins [11]. While parasites have access to metabolic pathways of the host, the reason why certain organisms that
live at high temperatures lack the methionine sulfoxide reduction system is
not understood. MsrA and MsrB genes are clustered in several bacterial genomes and often form an operon. Furthermore, MsrA and MsrB activities are
often detected in a single polypeptide formed via direct MsrA/MsrB fusion
[11,20]. Single MsrA and MsrB genes are present in yeast (e.g., Saccharomyces cerevisiae) and many animals (e.g., Caenorhabditis elegans and Drosophila melanogaster) [11]. On the other hand, multiple MsrA and/or MsrB genes
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Figure 1. A pathway of methionine sulfoxide reduction. R and S diastereomers of methionine sulfoxide are formed directly or indirectly in free methionines and protein
methionine residues in the presence of oxidants, such as hydrogen peroxide. Methionine-S-sulfoxides are reduced by MsrA and methionine-R-sulfoxides by MsrB with reductants, such as thioredoxin.

have been identified in the plant kingdom, for example in Arabidopsis thaliana [21,22] and Chlamydomonas reinhardtii [23].
MsrA was discovered decades ago, and its function, catalytic mechanism,
and structure are well understood [18,19,24–29]. MsrB has only recently been
identified and is currently being extensively characterized [11,30–34].
Mammalian methionine sulfoxide reductases
Human and mouse genomes contain a single MsrA gene [35]. Mammalian
MsrA has a typical N-terminal mitochondrial targeting peptide. Interestingly,
however, this protein is located in cytosol and nucleus as well as in mitochondria [36-38]. Although molecular mechanisms responsible for targeting this
protein to different cellular compartments are not fully understood, a recent
study has shown that structural and functional elements of MsrA play a role in
subcellular occurrence of this protein [38].
In contrast to a single MsrA gene [39,40], there are three MsrB genes in
mammals [41]. MsrB1 (also known as selenoprotein R or selenoprotein X)
[9,10] is a selenoprotein in which Sec occupies the active site. This protein resides in the cytosol and nucleus. The other two MsrBs are homologous proteins in which Cys residues are present in place of Sec. MsrB2 (also known as
CBS-1) [32,42] is a mitochondrial protein. Interestingly, human MsrB3 occurs
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in two protein forms, MsrB3A and MsrB3B. These two forms are generated
by alternative splicing of the first exon. The MsrB3A is targeted to the endoplasmic reticulum (ER), whereas MsrB3B is targeted to mitochondria [41].
However, there is no evidence for alternative splicing in the mouse MsrB3
gene. This protein contains the N-terminal ER signal followed by the mitochondrial signal sequence in a single coding region. This mouse MsrB3 form
resides in the ER [43]. These findings of multiple cellular locations of MsrA
and MsrB suggest that different compartments in mammalian cells maintain
the methionine reduction system to repair oxidized methionine residues.
Physiological roles of methionine sulfoxide reductases
Reversible interconversion between methionine and methionine sulfoxide
residues is implicated in several biological processes. Previously proposed
functions of methionine sulfoxide reductases include repair of damaged proteins, antioxidant function as scavengers of ROS, and regulation of protein
function [44,45].
A number of published reports describe the role of methionine sulfoxide
reductases in antioxidant defense. For example, overexpression of MsrA protected S. cerevisiae and human T cells against oxidative stress [46], and the corresponding homologs were implicated in the protection against ROS in many
microorganisms, such as Neisseria gonorrhoeae [47], Staphylococcus aureus
[48], and Helicobacter pylori [49]. Recently, MsrA was found to promote viability of lens cells [50] and retinal pigmented epithelial cells [51] by conferring resistance to oxidative stress. In addition, MsrA can play a protective role
against hypoxia/reoxygenation-mediated neuronal cell injury [52]. Lens MsrBs
were also found to play a role in resistance to oxidative stress [53]. In addition,
A. thaliana MsrA was reported to repair oxidatively damaged proteins during
dark by reducing methionine sulfoxides in these proteins [21].
Methionine sulfoxide reduction and aging
Methionine sulfoxide reductases are directly implicated in regulation of the
aging process. Research in this area has focused mainly on the effects of
MsrA. Deletion of the MsrA gene in mice decreased the lifespan by 40% [54],
whereas overexpression of MsrA in Drosophila extended it by 70% [55]. The
data that MsrA regulates lifespan in a variety of organisms raise a possibility
that MsrB may also play an important role in the aging process. In particular,
an attractive hypothesis has been advanced that since MsrB1 is a selenoprotein, dietary selenium supplementation may be used to increase expression of
this protein. If MsrB1 regulates lifespan, elevated levels of this protein due to
increased dietary intake of selenium may promote longevity in certain organisms or genetic backgrounds.
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The role of MsrB in aging has recently been tested using S. cerevisiae as a
model organism [56]. This protein was found to extend the yeast lifespan under caloric restriction conditions, whereas MsrA was most efficient under normal growth conditions. The lifespan extension required oxygen because it was
found that neither MsrA nor MsrB regulate the lifespan of yeast cells grown
under anaerobic conditions. In the future, deletion or overexpression of MsrB
genes in mammals is needed to investigate the roles of these proteins in mammalian aging. Characterization of the effect of overexpression of MsrA on the
lifespan in a mouse model also should be informative.
In addition to regulating lifespan, methionine sulfoxide reductases were
directly implicated in aging-related neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases [57-59].
Selenoprotein forms of methionine sulfoxide reductases
Although MsrBs are widely distributed in nature, the selenoprotein form of
MsrB has only been found in vertebrates. In contrast, vertebrate MsrAs are
Cys-containing proteins. Interestingly, a selenoprotein form of MsrA has also
been identified, but could only be detected in C. reinhardtii, a unicellular
green algae [23]. This Sec-containing MsrA has not been characterized. The
observation that both classes of methionine sulfoxide reductase can occur in
the form of selenoproteins suggests a catalytic advantage that Sec can offer in
protection against oxidation of methionine residues.
Catalytic properties and key role of selenium in MsrB
Both bacteria and eukaryotes share basic features of the Sec insertion machinery, such as SECIS element, Sec tRNA, and SECIS-binding protein. However,
a bacterial Sec insertion system also significantly differs from the mammalian
system [3, 60–63]. For example, the conserved sequences and structures of
SECIS elements are different in bacteria and eukaryotes. The location of these
structures is also different: bacterial SECIS elements are present within coding regions, immediately downstream of Sec-coding UGA codons, whereas
eukaryotic SECIS elements are located in the 3’-untranslated regions.
What is the role of the Sec residue in catalytic function of mammalian
MsrB1? By site-directed mutagenesis, a bacterial SECIS element was introduced immediately downstream of the in-frame UGA Sec codon, and the recombinant Sec-containing MsrB1 was expressed in Escherichia coli [41].
This recombinant selenoprotein MsrB1 had four mutations (S99R, S100L,
K102G, and F103P) compared to the wild type Sec-containing protein. The
mutant exhibited ~800-fold higher enzyme activity than the corresponding
Cys-containing form, indicating the essential role of Sec in this enzyme. In
addition, a separate study reported that a recombinant Sec-containing MsrB1
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expressed from a construct that contained the entire E. coli formate dehydrogenase H SECIS element in the coding region, had 100-200 fold higher
specific activity than the corresponding Cys mutant [64]. However, natural
mammalian Cys-containing enzymes, MsrB2 and MsrB3, also showed a high
enzyme activity [41].
Although the primary function of MsrA and MsrB is to catalyze the reduction of protein-based methionine sulfoxides, these enzymes can also reduce
free methionine sulfoxides, albeit with low activity. Consistent with this property, all three mammalian MsrBs exhibited the activity in the conversion of
free methionine-R-sulfoxide to methionine [41].
Some but not all MsrBs are zinc-containing proteins. This group of proteins includes all animal MsrBs, which contain a structural zinc coordinated
by two CXXC motifs (two Cys separated by two other residues) [11,41]. Mutation of any zinc-coordinating Cys to Ser in Drosophila MsrB resulted in
complete loss of metal and catalytic activity [34]. It has been suggested that
zinc plays a structural role in metalloprotein MsrBs, and that this metal is not
directly involved in the catalytic function [34,65].
Catalytic mechanisms of MsrB
The reaction mechanism of MsrA has been characterized biochemically and
is well supported by 3D structures [25–29]. Studies involving MsrBs from
D. melanogaster, N. gonorrhoeae, and N. meningitides [24,34,66] revealed
a similar catalytic mechanism. Interestingly, MsrA and MsrB folds are completely different [24,26-28,67]. MsrB functions in the following manner: 1) a
catalytic Cys attacks sulfoxide moiety of the substrate resulting in the formation of sulfenic acid intermediate and concomitant release of methionine; 2) a
resolving Cys attacks the sulfenic acid intermediate to form an intramolecular disulfide bond; and 3) a fully reduced enzyme is regenerated by reduction
of the disulfide with Trx, a natural electron donor. DTT can also reduce the disulfide in in vitro assays.
Multiple sequence alignments showed that ~60% of known MsrBs contain the conserved resolving Cys. The remaining ~40% of MsrB, including
all three mammalian MsrBs, do not have this Cys. In addition, some bacterial MsrBs have only a single Cys in their sequences, suggesting the lack of
any resolving Cys. How does the reaction proceed in these enzymes? Two alternative reaction mechanisms have been proposed. One is a direct reduction
of the sulfenic acid intermediate by Trx. The other is the use of an alternative
resolving Cys to form the intramolecular disulfide bond with the catalytic
Cys. The second possibility is supported by the recent study of Xanthomonas
campestris MsrB [68].
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Figure 2. Partial alignment of Sec- and Cys-containing MsrBs. Catalytic Cys (C) and
Sec (U) residues are shown by an arrow. The conserved His, Val/Ile, and Asn residues
in Cys-containing proteins are indicated by arrowheads, and the corresponding residues (Gly, Glu, and Phe, respectively) in mouse selenoprotein MsrB1 are indicated
by bold letters. Numbering of ammo acids is based on the mouse MsrB1 sequence.
Cys71 and Cys74 coordinate zinc, and the corresponding CxxC motif is conserved
in many, but not all MsrBs. Accession numbers (GI) are as follows: Mus musculus
MsrB1, 7305478; M. musculus MsrB2, 27753987; Homo sapiens MsrB3, 72534836;
Drosophila melanogaster, 17944415; Saccharomyces cerevisiae, 6319816; Arabidopsis thaliana, 4115939; Escherichia coli, 15802192; Methanothermobacter thermautotrophicus, 15678738; Agrobacterium tumefaciens, 15888246; Mycobacterium tuberculosis, 15609811; Salmonella enterica, 16760604; Vibrio cholerae, 15642000;
Helicobacter pylori, 3252888; Hemophilus influenzae, 16273361; Neisseria gonorrhoeae, 19526685.

Different sets of active site features in selenoprotein and
non-selenoprotein MsrB
Multiple sequence alignments reveal three highly conserved residues in MsrB
sequences. These three residues are present in Cys-containing MsrBs, but absent in selenoprotein forms of this enzyme (Figure 2). It was previously found
that these residues are part of the active site. Why did selenoprotein MsrBs
evolve different residues in these positions? What are the roles of these residues in the catalytic function of selenoprotein and Cys-containing MsrBs?
It was recently found that the three residues uniquely conserved in Cys-containing MsrBs are critical for enzyme activity in MsrB2 and MsrB3, yet introducing these residues into MsrB1 inactivates this selenoprotein. Interestingly,
when these residues are introduced into the Cys-containing mutant of MsrB1,
the activity of this mutant increases several fold. Thus, the three residues are
required for Cys-containing MsrB forms, but detrimental for the Sec-contain-
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Figure 3. Models for catalytic mechanisms of Sec- and Cys-containing MsrBs. In Seccontaining MsrB1, the catalytic Sec attacks the methionine-R-sulfoxide (Met-R-SO) to
form a selenenic acid intermediate, which interacts with a resolving Cys and forms a
selenenylsulfide bond. This selenenylsulfide bond, subsequently, is reduced by Trx. In
contrast, in Cys-containing MsrB2 and MsrB3, a sulfenic acid intermediate can be directly reduced by Trx because the resolving Cys is dispensable.

ing forms. These data suggested that Sec- and Cys-containing MsrBs evolve
distinct sets of active site features to maximize their catalytic efficiencies.
Different catalytic mechanisms between selenoprotein and
non-selenoprotein mammalian MsrBs
As discussed above, many selenoproteins have fully functional orthologs,
wherein Cys replaces Sec. These Cys orthologs are often catalytically as efficient as selenoprotein forms. The reason why Sec is used in proteins if the
Cys versions are sufficient for their functions is only beginning to be understood. The three mammalian MsrBs offer a great model system to address
these questions which are central to the role of selenium in biology. We recently reported that selenoprotein and non-selenoprotein forms of mammalian
MsrBs employ different catalytic mechanisms with respect to the regeneration
of the fully reduced proteins (Figure 3) [69].
As shown in Figure 3, the selenoprotein MsrB1 requires a unique resolving
Cys for recycling of the enzyme. A selenenic acid intermediate of MsrB1 is engaged in a selenenylsulfide bond with resolving Cys located in the N-terminal
part of the protein. Mutation of this Cys to Ser results in complete loss of enzyme activity in the Trx-dependent reaction but not in the DTT-dependent reaction. Subsequently, the selenenylsulfide is reduced by a physiological electron
donor, Trx. It appears that the selenenic acid intermediate cannot be reduced by
Trx but is reducible by DTT. In contrast, mutational analyses revealed that the
resolving Cys is not needed for Cys-containing MsrB2 and MsrB3, in which
the sulfenic acid intermediate is likely directly reduced by Trx.
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Catalytic advantages and disadvantages of Sec-containing proteins
compared to Cys-containing counterparts
The data on Sec- and Cys-containing MsrBs suggested that Sec per se may
result in a higher catalytic activity. Replacement of Cys with Sec in mammalian MsrB2 and MsrB3 increased the activity over 100 fold in the DTTdependent reaction [69]. It has been previously reported that the catalytic
activity of phospholipid hydroperoxide glutathione peroxidase can also be
increased by replacing the active site Cys with Sec [70]. Thus, the enhanced
catalytic activity of selenoproteins can explain, at least in part, the advantage
of Sec over Cys. However, replacement of Cys with Sec may not only influence enzyme activity, but also alter protein function. For instance, a Seccontaining form of subtilisin is an efficient peroxidase rather than a protease
[71]. The use of Sec in glutathione S-transferase also changed this protein to
a peroxidase [72].
Are there any other advantages of the use of selenium besides enhancing
enzyme activity? A recent study has shown that the presence of a unique Cterminal active site in Drosophila thioredoxin reductase (SCCS instead of
GCUG in mammalian enzymes) can convert this protein into a highly active
enzyme [73]. This study suggested that the advantages of selenoenzymes are
in a broader range of substrates and flexibility of microenvironmental conditions in the active sites.
It appears that the use of Sec can also result in catalytic disadvantages.
Although the mutant Sec-containing forms of MsrB2 and MsrB3 are characterized by a 100-fold increased methionine sulfoxide reductase activity, regeneration of the active enzymes by natural electron donor (e.g., Trx) is not
possible [69]. However, by introducing a unique resolving Cys, the selenoprotein form of MsrB3 can become as active as the natural Cys-containing enzyme in the Trx-dependent reaction [69].
Evolutionary implications
Most selenoprotein forms likely evolved by replacing catalytic Cys with Sec,
which equips oxidoreductases with enhanced activity. However, this evolutionary process is more complex than a simple change of a Cys codon to
TGA. The changes must also involve the generation of SECIS elements. Furthermore, Sec may evolve only in environments where selenium is present in
sufficient levels and in organisms with active Sec insertion system. Clearly,
although replacement of catalytic redox Cys with Sec may be expected to
enhance protein function, other requirements should be satisfied. These and
other factors may limit the use of Sec in biological systems.
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